

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Predictors of risk of fracture in inflammatory bowel diseases: a prospective study using FRAX score**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1741900> since 2020-07-11T09:47:03Z

*Published version:*

DOI:10.23736/S1121-421X.20.02672-0

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

## **Predictors of risk of fracture in inflammatory bowel diseases: a prospective study using FRAX score**

Journal: Minerva Gastroenterologica e Dietologica

Paper code: Minerva Gastroenterol Dietol-2672

Submission date: January 14, 2020

Article type: Original Article

Files:

1. Manuscript

Version: 1

Description: manoscritto

File format: application/vnd.openxmlformats-officedocument.wordprocessingml.document

2. Figures 1

Version: 1

Description: Figure 1

File format: image/tiff

3. Figures 2

Version: 1

Description: Figure 2

File format: image/tiff

4. Figures 3

Version: 1

Description: Figure 3

File format: image/tiff

**Predictors of risk of fracture in inflammatory bowel diseases: a prospective study using  
FRAX score**

Davide Giuseppe Ribaldone<sup>1</sup> \*, Massimo Procopio<sup>2</sup>, Rinaldo Pellicano<sup>3</sup>, Marco Barale<sup>2</sup>, Gabriele Giudici<sup>1</sup>, Mario Morino<sup>4</sup>, Giorgio Maria Saracco<sup>1</sup>, Marco Astegiano<sup>3</sup>

<sup>1</sup> Department of Medical Sciences, Division of Gastroenterology, University of Turin, Turin, Italy

<sup>2</sup> Department of General and Specialty Medicine, Division of Endocrinology, Diabetology and Metabolic Diseases, Molinette Hospital, University of Turin, Italy

<sup>3</sup> Unit of Gastroenterology, Molinette Hospital, Turin, Italy

<sup>4</sup> Department of Surgical Sciences, University of Turin, Turin, Italy

Conflicts of interest: none to declare.

\*Corresponding author: Davide Giuseppe Ribaldone, Department of Medical Sciences, Division of Gastroenterology, C.so Bramante 88, 10126 Turin, Italy; tel (0039)0116333918, fax (0039)0116333623, davrib\_1998@yahoo.com

**Abstract**

**BACKGROUND:** Despite the well-known risk of osteoporosis and bone fractures among patients with inflammatory bowel diseases, the WHO FRAX tool has been used in a limited number of studies in this specific population. The purpose of this study was to search for predictors of risk of fractures assessed by FRAX score.

**METHODS:** We prospectively calculated FRAX score for hip and major osteoporotic fractures in inflammatory bowel disease patients consecutively recruited.

**RESULTS:** The mean risk of hip fractures at 10 years, for the 80 recruited patients, resulted 1.4%, while the mean risk of major osteoporotic fractures was 7.8%. The risk of hip fractures was 1.3% among the 30 Crohn's disease patients versus 1.4% ( $p = 0.82$ ) among 50 ulcerative colitis patients. A prolonged use of corticosteroids correlated with a tendency to a greater risk of hip fracture ( $r = 0.38$ ,  $p = 0.08$ ). Patients with normal erythrocyte sedimentation rate (ESR) values had a risk of osteoporotic hip fractures of 0.75%, while those with high ESR values had a risk of 1.86% ( $p = 0.04$ ). Regarding the risk of major bone fractures, patients with normal ESR values had a risk of 5.9%, versus a risk of 18% in those with elevated ESR ( $p = 0.03$ ).

**CONCLUSIONS:** The correlation between increase of inflammatory markers and increased risk of osteoporotic fractures and the lack of difference between Crohn's disease and ulcerative colitis suggest a central role of inflammation over malabsorption in this population.

**Key words:** Vitamin D – Crohn's disease – Malabsorption – Osteoporosis – Ulcerative colitis

## Introduction

Osteoporosis is a widespread disease of bone, characterized by a compromise of resistance of bone to mechanical stress, a reduction in quantity and an alteration of quality of its mineralization that cause fragility predisposing to an increased risk of fractures.<sup>1</sup> Secondary osteoporosis is caused by endocrinopathies, neoplasms, gastrointestinal (GI) diseases, kidney diseases, rheumatic, genetic and iatrogenic causes.<sup>2</sup>

Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders, classified as Crohn's disease (CD) and ulcerative colitis (UC). In CD, inflammation of GI wall can affect any tract in a non-continuous way and with a transmural involvement; in UC, instead, lesions are continuous and confined to superficial layer of colonic mucosa.<sup>3,4</sup> Although the pathogenesis of IBDs as well as of their extra-intestinal manifestations<sup>5</sup> remain to be elucidated, an increasing interest is focalized on the potential role of microbiota in the interaction between the immune system and environmental factors in genetically predisposed individuals.<sup>6-8</sup>

It has been shown that bone mineral density (BMD) levels are lower in IBD patients than in healthy controls: 22-77% of patients with IBDs have osteopenia, while 12-41% of cases have osteoporosis. While some previous study reported that CD patients showed higher prevalence of lower BMD than UC patients, recent studies have shown similar incidence rates for the two diseases.<sup>9</sup> The American Gastroenterology Association, the American College of Gastroenterology and the British Society of Gastroenterology recommend systematic evaluation of BMD in IBD patients who present additional risk factors for osteoporotic fractures, such as age over 60 years, cumulative exposure to corticosteroids over 3 months, low body mass index (BMI), family and personal history of fractures due to minor trauma or hypogonadism.<sup>10-12</sup> Despite the existence of guidelines and availability of effective treatments for osteoporosis, this disease is currently under-diagnosed and under-treated in both women and men.<sup>13</sup> The densitometric value does not identify with certainty a future bone fracture. Hence, it is increasingly evident that the assessment of risk of fracture should also include

1 other factors identified by the World Health Organization (WHO) as being able to influence the  
2 probability of osteoporotic fractures. Among those, personal and family history of pathological  
3 fractures, use of corticosteroid therapies, smoking and alcohol habits and low BMI are the most  
4 important.<sup>14,15</sup> These variables are linked by a predictive free-use algorithm called the fracture risk  
5 assessment tool (FRAX score).  
6  
7  
8  
9

10  
11  
12 The aim of this study was to search for predictors of risk of fracture in IBD patients assessed by  
13 FRAX score.  
14  
15  
16  
17  
18  
19  
20

### 21 **Materials and Methods**

22  
23 From November 2018 to February 2019 all consecutive patients affected by IBDs followed in our  
24 IBD outpatient clinic (already described in other studies<sup>16</sup>) were prospectively included in the study.  
25  
26  
27

28 Inclusion criteria was a confirmed diagnosis of IBDs.<sup>17</sup>  
29

30 Exclusion criteria were:  
31

- 32 - pregnancy
- 33 - a chronic kidney disease
- 34 - a previous history of pathologic fracture.
- 35
- 36
- 37
- 38
- 39
- 40

41 The risk factors analysed for a higher FRAX score were: sex, age, BMI, and smoking habits, risk  
42 factors for secondary osteoporosis, duration of IBDs, type of IBD, location of the disease, bowel  
43 surgical interventions, clinical (partial MAYO score for UC and Harvey-Bradshaw index [HBI] for  
44 CD) activity at the time of recruitment and endoscopic (endoscopic MAYO score for UC and SES-  
45 CD score for CD) activity within 6 months before the time of recruitment, therapy with mesalazine,  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

1 corticosteroids, immunosuppressive drugs, biological drugs, inflammatory indexes (erythrocyte  
2  
3 sedimentation rate [ESR], C reactive protein [CRP], faecal calprotectin.<sup>18</sup>  
4

5  
6 The study was conducted in accordance with International Council for Harmonisation of Technical  
7  
8 Requirements for Pharmaceuticals for Human Use (ICH)-Good Clinical Practice guidelines, the  
9  
10 Declaration of Helsinki, and local laws and regulations. The protocol was approved by the  
11  
12 appropriate independent ethics committees and patients gave written informed consent.  
13

### 14 15 16 17 *Statistical analysis*

18  
19 Regarding the continuous variables, to compare the mean of two independent samples, T-test was  
20  
21 used in all cases in which the data were normally distributed, otherwise the Mann-Whitney test was  
22  
23 used.  
24

25  
26 Regarding the categorical variables, the chi-square test was used.

27  
28 The level of statistical significance was set at 95%, so the results of all analyses were considered  
29  
30 significant for p values of <0.05.  
31

32  
33 The statistical analysis was performed with MedCalc Statistical Software version 14.8.1 (MedCalc  
34  
35 Software bvba, Ostend, Belgium; <http://www.medcalc.org>; 2014).  
36  
37  
38  
39

## 40 41 42 **Results**

43  
44 Of 82 included patients, two were lost to follow-up. The clinical characteristics of the remaining 80  
45  
46 patients are reported in Table 1.  
47  
48  
49  
50

51  
52  
53  
54  
55  
Table 1.

1 As regards the inflammatory indices, ESR was measured in 70 patients, of whom 40 had a normal  
2 value (57.1%), and in 30 was increased (42.9%). CRP was normal in 48 patients (61.5%) and  
3 increased in 30 patients (38.5%). Faecal calprotectin values were available in 70 patients, with a range  
4 from 7 to 6000  $\mu\text{g/g}$ , with a geometric mean of 216  $\mu\text{g/g}$ . As regards treatments, all patients in the  
5 study took oral mesalazine, with a range from 2 months to 504 months (mean = 157.3 months/patient).  
6  
7 Out of 80 patients, 66 assumed systemic corticosteroid therapy at a dosage of 5 mg/day or more; total  
8 duration of corticosteroid therapy varied from 2 to 299 months (mean = 18.9 months/patient). Out of  
9 80 patients, 40 assumed immunosuppressive therapy (methotrexate, azathioprine or other  
10 immunosuppressants) for at least a month: the duration of this treatment ranged from 1 to 124 months  
11 with an average of 41 months. Finally, 18 patients were treated with biological drugs for a period of  
12 time ranging from 3 to 60 months (mean = 28.1 months/patient).  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 The risk of hip fractures at 10 years, calculated through FRAX score, ranged between 0.1% and  
26 24% (mean = 1.4%). The risk of fractures in the 30 CD patients resulted 1.3% versus 1.4% ( $p = 0.82$ )  
27 among the 50 UC patients. The correlation coefficient between disease duration and fracture risk  
28 resulted  $r = 0.02$  ( $p = 0.88$ ). In the 30 CD patients, ileal or ileo-colic localization conferred a fracture  
29 risk of 1.26%, while exclusive colic localization conferred a risk of fracture of 1.41% ( $p = 0.89$ ).  
30 Among the 50 cases of UC, in 22 with a disease limited to left colon the risk of fractures was 1.38%,  
31 while in 28 patients with an extensive localization the risk of fractures was 1.4% ( $p = 0.92$ ). Among  
32 the 30 CD patients, 18 have undergone to at least one surgical resection in their lives: in this case the  
33 risk of hip fracture was 1.16%, while in absence of previous surgical history it resulted 1.49% ( $p =$   
34 0.72). Since only 2 of the UC-recruited patients underwent surgery in their lifetime, it was not possible  
35 to evaluate the correlation between hip fracture risk and surgery in UC cases. Clinical and endoscopic  
36 disease activity did not significantly affect the risk of osteoporotic hip fracture at 10 years, as  
37 significance levels of the correlations were respectively  $p = 0.52$  and  $p = 0.59$ . Taking into  
38 consideration medical therapy, the correlation between mesalazine intake and risk of hip fractures at  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55



1 10 years was not statistically significant, being the correlation coefficient  $r = -0.05$  and the  
2  
3 significance level  $p = 0.77$ . Considering a cut-off of a minimum of 12 cumulative months of systemic  
4  
5 corticosteroids  $>5$  mg/day, these patients showed a tendency to a greater risk of hip fracture at 10  
6  
7 years ( $r = 0.38$  and  $p = 0.08$ ). The association between use of immunosuppressants and FRAX score  
8  
9 was not statistically significant ( $r = 0.1$  and  $p = 0.67$ ). The risk of hip fractures at 10 years correlated  
10  
11 with use of biological drugs was not significant ( $r = -0.23$ ,  $p = 0.55$ ), but there was a tendency towards  
12  
13 an inverse relationship between the two factors. As shown in Figure 1, 40 patients with normal ESR  
14  
15 values had a risk of osteoporotic hip fractures at 10 years of 0.75%, while 30 patients with high ESR  
16  
17 values had a risk of 1.86% ( $p = 0.04$ ).  
18  
19  
20  
21  
22  
23

24 Figure 1  
25  
26  
27  
28  
29

30 High CRP values were not associated to a different risk of osteoporotic hip fractures at 10 years  
31  
32 (probability of fracture in the 48 patients with normal PCR = 1.3%, probability in the 30 patients with  
33  
34 high level of PCR = 1.4%,  $p = 0.88$ ). The correlation between faecal calprotectin levels (considering  
35  
36 values  $>300$   $\mu\text{g/g}$ , i.e. active bowel inflammation) and risk of fracture was  $r = 0.39$  ( $p = 0.15$ ) (Figure  
37  
38 2).  
39  
40  
41  
42  
43

44 Figure 2  
45  
46  
47  
48  
49

50 The risk of major osteoporotic fractures at 10 years, calculated with FRAX score, was between 2.5%  
51  
52 and 46%, with an average risk of 7.8%. The probability of major fractures was not associated with  
53  
54 disease duration (correlation coefficient  $r = 0.12$ ,  $p = 0.45$ ). The 30 CD patients did not show a  
55

1 significantly different risk of major osteoporotic fractures compared to the 50 UC patients: in the first  
2  
3 group the probability resulted 7.9% while in the second group 7.6% ( $p = 0.88$ ). Regarding CD patients,  
4  
5 24 subjects with ileal localization had a risk of major osteoporotic fractures of 7.6%, those with  
6  
7 exclusively colic localization of 9.2% ( $p = 0.67$ ). Regarding UC, 22 patients with a disease limited to  
8  
9 left colon had an average risk of 8.3%, while in 28 cases of extensive disease the risk was 7.2% ( $p =$   
10  
11 0.6). Among 18 CD patients with a history of surgical resection the risk of major osteoporotic  
12  
13 fractures was 7.5%, versus 8.5% in those never operated ( $p = 0.73$ ). The clinical activity, evaluated  
14  
15 at the time of visit, did not correlate with a greater risk of major osteoporotic fractures: 70 patients  
16  
17 with remission / mild activity had a risk of 7.9%, while 10 patients with moderate / severe disease  
18  
19 activity had a risk of 6.8% ( $p = 0.62$ ). Similarly, endoscopic disease activity was not correlated with  
20  
21 an increased risk of major bone fractures: 62 patients in remission / mild endoscopic activity had a  
22  
23 risk of 8.1%, while 18 patients with moderate / severe endoscopic activity had a risk of 6.8% ( $p =$   
24  
25 0.47). Regarding drugs consumption, mesalazine did not influence the value of the FRAX score for  
26  
27 major osteoporotic fractures ( $p = 0.63$ ), as well as immunosuppressive therapy ( $p = 1$ ). Forty-six  
28  
29 patients with corticosteroid treatment for at least 12 months in their lifetime showed a statistically  
30  
31 significant increase risk of major osteoporotic fractures ( $p = 0.03$ ). In the 18 patients who received  
32  
33 anti-tumor necrosis factor (TNF) drugs, there was a non-significant reduction in risk of fractures, with  
34  
35 an inverse correlation index ( $r = -0.38$ ,  $p = 0.32$ ). ESR values were statistically significantly correlated  
36  
37 with the risk of major bone fractures: as shown in Figure 3, the 40 patients with normal ESR values  
38  
39 had a 10-year risk of 5.9%, versus a risk of 18% in patients with elevated ESR ( $p = 0.03$ ).  
40  
41  
42  
43  
44  
45  
46  
47

48 Figure 3  
49  
50  
51  
52  
53  
54  
55

1 CRP values were not correlated with a greater risk of major osteoporotic fractures ( $p > 0.6$ ). The  
2  
3 correlation of faecal calprotectin values with risk of major osteoporotic fractures was not statistically  
4  
5 significant ( $r = 0.31$ ,  $p = 0.26$ ).  
6  
7  
8  
9

## 11 Discussion

14 Despite the well-known increased risk of osteoporosis and bone fractures among IBD patients, the  
15 WHO FRAX tool has been used in a very limited number of studies in this specific population. After  
16 an exhaustive literature search, only 7 documents, 3 of them being abstracts only, have reported on  
17 the use of the FRAX tool to estimate the 10-year probability of hip and major osteoporotic fractures  
18 in patients with IBDs<sup>19</sup>. Summary estimates have shown a low risk of hip fracture in IBD patients  
19 (below a 4% fracture risk after 10 years), and also a modest increase in 10-year probability of  
20 suffering a major osteoporotic fracture (below 12%).<sup>19</sup> The potential advantages of using FRAX tool  
21 with IBD patients include the fact that it allows the assessment of additional risk factors related to  
22 loss of bone mass and associated to IBDs beyond BMD itself, including older age, postmenopausal  
23 status, smoking, malnutrition, physical inactivity, corticosteroid use for more than 3 months.<sup>20</sup>  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 Our study highlights the lack of correlation between FRAX score and clinical or endoscopic disease  
36 activity, and therapy with immunosuppressants. Regarding the risk of major and hip osteoporotic  
37 fractures at 10 years, none of the parameters related to the characteristics of IBD (type, location,  
38 duration) is related to a greater significant attributable risk of fracture. Consistent with what has been  
39 known for a long time about biological effects of corticosteroid therapy on bone metabolism, these  
40 drugs significantly increase the risk of major fractures ( $p = 0.03$ ): it has been identified as cut-off,  
41 above which this risk occurs, a minimum duration of therapy equal to 12 cumulative months, with a  
42 minimum posology of 5 mg/day of systemic steroids. Focusing on the risk of hip fractures, there is a  
43 similar trend ( $p = 0.08$ ), which however, perhaps due to the low sample size, does not reach the level  
44 of statistical significance. The increase in systemic inflammatory parameter (ESR) also correlates  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

1 with an increased risk of fractures; in particular, in case of major fractures the risk passes from 5.9%  
2  
3 (normal ESR) to 9.02% (increased ESR) ( $p = 0.03$ ), while in case of hip fractures the risk passes from  
4  
5 0.75% to 1.86% ( $p = 0.04$ ).  
6

7 The message that emerges from our study is that, regardless of type of IBD, extent of the lesions,  
8  
9 duration of disease, patient's gender and age, the systemic and local inflammation parameters are  
10  
11 those that weigh more on imbalance of metabolic state of the bone. The association between high  
12  
13 ESR levels and the risk of fractures, in fact, highlights the role of IBD-related inflammation. In the  
14  
15 case of calprotectin, an index of site-specific inflammation,<sup>18</sup> the correlation with the risk of fractures  
16  
17 (despite not significant due to the low sample size) reinforces the hypothesis that local inflammatory  
18  
19 factors, in synergy with systemic ones, make a greater contribution to metabolic bone alterations  
20  
21 compared to the only compromise of absorption. In interpreting the obtained data, the role assumed  
22  
23 by systemic corticosteroid therapy in worsening of bone balance also appears evident. It is difficult  
24  
25 to discriminate if the worsening of bone structure is attributable solely to the IBD-related  
26  
27 inflammatory state<sup>21</sup> or to the use of systemic steroid when inflammation is higher or whether there  
28  
29 is a synergy between the two mechanisms. The fact that previous surgical interventions were not  
30  
31 correlated with an increased risk of fractures highlights the role of the inflammation over that of the  
32  
33 absorption in determining the risk of fracture. Patients who have undergone surgery, in fact, tend to  
34  
35 be exposed to a reduced local and systemic inflammatory stimulus following surgery, thanks to the  
36  
37 resection of the tract affected by pathology. This could on the other hand determine a recovery, at  
38  
39 least partial, of the bone mass previously lost.  
40  
41  
42  
43

44 From the pathogenetic point of view, the most accepted hypothesis is that the connection between  
45  
46 reduced BMD and IBDs resides in complex cytokine mechanisms: the signalling by the receptor  
47  
48 activator of nuclear factor kappa-B ligand (RANK-L) molecule, in fact, involved in osteoclastic  
49  
50 activation, seems to be increased in conditions of high levels of (interleukin) (IL)1, IL6 and  $TNF\alpha$ ,  
51  
52 inflammatory cytokines present at local and systemic level in IBDs.<sup>22</sup> The role of  $TNF\alpha$ , in fact,  
53  
54 consists in inhibiting the differentiation of osteoblasts by inducing that of osteoclasts,<sup>23</sup> in synergy  
55

1 with IL1, it also contributes to bone resorption by stimulating the osteoclastic production of IL6,  
2  
3 which in turn stimulates osteoclastic activation.<sup>24</sup> In this regard, use of biological drugs such as  
4  
5 infliximab (anti-TNF) in IBD patients seems to normalize activation of this cytokine pathway.<sup>25</sup>  
6  
7

### 8 9 *Limitations of the study*

10 Some critical issues should be considered. First, the small sample size as well as the heterogeneous  
11  
12 population represent the main limitations of this study. However, the potential bias arising from this  
13  
14 is partially limited by the fact that in our IBD outpatient clinic all authors follow International  
15  
16 Guidelines.<sup>17</sup> Furthermore, during the last twenty years, all consultations have been recorded in both  
17  
18 a paper archive and a computerized data bank. Second, a comparison with a control group is lacking,  
19  
20 but the aim of our study was to find predictors of an increased risk of osteoporotic fractures in IBD  
21  
22 patients and not the comparison of the risk of fracture in IBD patients with other populations (a topic  
23  
24 already widely studied in literature).  
25  
26  
27  
28  
29  
30

### 31 **Conclusions**

32  
33  
34 In conclusion, the correlation between increase of ESR, negative history for surgical resections and  
35  
36 increase in faecal calprotectin values with an increased risk of osteoporotic fractures at FRAX score  
37  
38 suggest the central role of inflammation as the main actor of loss of bone mineral mass in IBD patients.  
39  
40 It is therefore essential, in order to minimize the osteoporotic risk among IBD patients, to focus  
41  
42 clinical and therapeutic management on control of exacerbation events and on normalization of  
43  
44 systemic and local inflammatory parameters. In this regard, the pro-resorbing role of corticosteroids  
45  
46 is confirmed, while administration of anti-TNF drugs appears to improve bone mineral mass.  
47  
48  
49  
50

### 51 **References**

- 52  
53  
54 1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.  
55

- 1 Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1–129.
- 2
- 3
- 4 2. Colangelo L, Biamonte F, Pepe J, Cipriani C, Minisola S. Understanding and managing
- 5 secondary osteoporosis. *Expert Rev Endocrinol Metab.* 2019 Jan 27;14:111–22.
- 6
- 7
- 8
- 9 3. Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European
- 10 Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part
- 11 1: Diagnosis and Medical Management. *J Crohn's Colitis.* 2017 Jan;11(1):3–25.
- 12
- 13
- 14
- 15
- 16 4. Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, et al. 3rd
- 17 European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease
- 18 2016: Part 2: Surgical Management and Special Situations. *J Crohns Colitis.* 2017
- 19 Feb;11(2):135–49.
- 20
- 21
- 22
- 23
- 24
- 25
- 26 5. Ribaldone DG, Pellicano R, Actis GC. The gut and the Inflammatory Bowel Diseases inside-
- 27 out: the extra-intestinal manifestations. *Minerva Gastroenterol Dietol.* 2019 Apr 16;
- 28
- 29
- 30
- 31 6. Ribaldone DG, Caviglia GP, Abdulle A, Pellicano R, Ditto MC, Morino M, et al.
- 32 Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease. *J Clin Med.* 2019
- 33 Oct 9;8(10):1646.
- 34
- 35
- 36
- 37
- 38 7. Caviglia GP, Rosso C, Ribaldone DG, Dughera F, Fagoonee S, Asteigano M, et al.
- 39 Physiopathology of intestinal barrier and the role of zonulin. *Minerva Biotechnol.*
- 40 2019;31(3):83–92.
- 41
- 42
- 43
- 44
- 45 8. Masoodi I, Alshanteeti AS, Ahmad S, Alyamani EJ, Al-Lehibi AA, Qutub AN, et al.
- 46 Microbial dysbiosis in inflammatory bowel diseases: results of a metagenomic study in Saudi
- 47 Arabia. *Minerva Gastroenterol Dietol.* 2019 Sep;65(3):177–86.
- 48
- 49
- 50
- 51
- 52 9. Etzel JP, Larson MF, Anawalt BD, Collins J, Dominitz JA. Assessment and management of
- 53 low bone density in inflammatory bowel disease and performance of professional society
- 54
- 55

- 1 guidelines. *Inflamm Bowel Dis*. 2011 Oct;17(10):2122–9.
- 2
- 3
- 4 10. Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac disease and
- 5
- 6 inflammatory bowel disease. *British Society of Gastroenterology. Gut*. 2000 Jan;46 Suppl
- 7
- 8 1:i1-8.
- 9
- 10
- 11 11. American Gastroenterological Association medical position statement: guidelines on
- 12
- 13 osteoporosis in gastrointestinal diseases. *Gastroenterology*. 2003 Mar;124(3):791–4.
- 14
- 15
- 16 12. Kornbluth A, Hayes M, Feldman S, Hunt M, Fried-Boxt E, Lichtiger S, et al. Do guidelines
- 17
- 18 matter? Implementation of the ACG and AGA osteoporosis screening guidelines in
- 19
- 20 inflammatory bowel disease (IBD) patients who meet the guidelines' criteria. *Am J*
- 21
- 22 *Gastroenterol*. 2006 Jul;101(7):1546–50.
- 23
- 24
- 25
- 26 13. Cunningham TD, Di Pace BS, Ullal J. Osteoporosis treatment disparities: a 6-year aggregate
- 27
- 28 analysis from national survey data. *Osteoporos Int*. 2014 Sep 5;25(9):2199–208.
- 29
- 30
- 31 14. Sambrook P, Cooper C. Osteoporosis. *Lancet (London, England)*. 2006 Jun
- 32
- 33 17;367(9527):2010–8.
- 34
- 35
- 36 15. Pellicano R, Ribaldone DG. Osteoporosis, osteopenia, and inflammatory bowel disease:
- 37
- 38 lessons from a real-world study. *Polish Arch Intern Med*. 2018;128(7–8):411–3.
- 39
- 40
- 41 16. Ribaldone DG, Manetta T, Mengozzi G, Saracco GM, Pellicano R, Astegiano M.
- 42
- 43 Adalimumab trough levels predict Crohn's disease clinical course. *Dig Liver Dis*.
- 44
- 45 2018;50:204–6.
- 46
- 47
- 48 17. Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al. ECCO-ESGAR
- 49
- 50 Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known
- 51
- 52 IBD, detection of complications. *J Crohn's Colitis*. 2019 Feb 1;13(2):144–64.
- 53
- 54
- 55

- 1 18. Caviglia GP, Ribaldone DG, Rosso C, Saracco GM, Astegiano M, Pellicano R. Fecal  
2 calprotectin: beyond intestinal organic diseases. *Panminerva Med.* 2018 Mar;60(1):29–34.  
3  
4
- 5 19. Serrano-Montalbán B, Arias Á, Friginal-Ruiz AB, Lucendo AJ. The Use of the Fracture Risk  
6 Assessment (FRAX®) Tool in Predicting Risk of Fractures in Patients With Inflammatory  
7 Bowel Disease: A Systematic Review. *J Clin Densitom.* 2017 Apr;20(2):180–7.  
8  
9
- 10 20. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among  
11 patients with inflammatory bowel disease. A population-based cohort study. *Ann Intern Med.*  
12 2000 Nov 21;133(10):795–9.  
13  
14
- 15 21. Ribaldone DG, Pellicano R, Actis GC. Inflammation: a highly conserved, Janus-like  
16 phenomenon-a gastroenterologist' perspective. *J Mol Med (Berl).* 2018 Jul 9;96(9):861–71.  
17  
18
- 19 22. Ghishan FK, Kiela PR. Advances in the understanding of mineral and bone metabolism in  
20 inflammatory bowel diseases. *Am J Physiol Liver Physiol.* 2011 Feb;300(2):G191–201.  
21  
22
- 23 23. Gilbert L, He X, Farmer P, Boden S, Kozłowski M, Rubin J, et al. Inhibition of Osteoblast  
24 Differentiation by Tumor Necrosis Factor- $\alpha$ <sup>1</sup>. *Endocrinology.* 2000 Nov;141(11):3956–64.  
25  
26
- 27 24. Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, et al. The mouse/human  
28 chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice  
29 from cachexia and TNF lethality in vivo. *Cytokine.* 1995 Jan;7(1):15–25.  
30  
31
- 32 25. Miheller P, Muzes G, Rácz K, Blázovits A, Lakatos P, Herszényi L, et al. Changes of OPG  
33 and RANKL concentrations in Crohn's disease after infliximab therapy. *Inflamm Bowel Dis.*  
34 2007 Nov;13(11):1379–84.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55



Table 1. Clinical features of patients with inflammatory bowel disease included in the study

	All patients	CD	UC
<b>Sex</b>			
Males (n)	52	18 (60%)	34 (68%)
Females (n)	28	12 (40%)	16 (32%)
<b>Age (mean, range)</b>	52.1, 18-82	53.2, 18-82	50.9, 19-79
<b>BMI (mean, range)</b>	25.3, 17.3-39.3	23.9, 17.3-30.1	26.5, 19.1-39.3
<b>Diagnosis (n, %)</b>		30 (37.5%)	50 (62.5%)
<b>Disease duration (mean years, range)</b>	15.3, 0-48	16.9, 1-48	14, 0-37
<b>Smoking habits (n, %)</b>			
Active smoke / ex-smoker	24 (30%)	20 (66.7%)	30 (60%)
Non smoker	56 (70%)	10 (33.3%)	20 (40%)
<b>IBD location (n, %)</b>			
Ileum / ileum-colon		24 (80%)	
Colon		6 (20%)	
Until left flexure			22 (44%)
Extensive colitis			28 (56%)
<b>Surgery (n, %)</b>			
Yes	20 (25%)	18 (60%)	2 (4%)

No	60 (75%)	12 (40%)	48 (96%)
<b>Clinical activity (n)</b>			
Remission / slight activity	70	22	48
Moderate / severe activity	10	8	2
<b>Endoscopic activity (n)</b>			
Remission / slight activity	62	26	36
Moderate / severe activity	18	4	14


CD = Crohn's disease; UC = ulcerative colitis; N = number; BMI = body mass index; IBD = inflammatory bowel disease

1 Figure 1. FRAX Score (risk of osteoporotic hip fractures at 10 years) and erythrocyte sedimentation  
2  
3 rate.  
4

5  
6 Figure 2. FRAX score (risk of osteoporotic hip fractures at 10 years) and calprotectin values  
7

8  
9 Figure 3. FRAX score (risk of major osteoporotic fractures at 10 years) and erythrocyte  
10 sedimentation rate  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55


PEER REVIEW COPY  
Minerva Gastroenterologica e Dietologica




PEER REVIEW COPY  
Minerva Gastroenterologica e Dietologica

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55





PEER REVIEW COPY  
Minerva Gastroenterologica e Dietologica

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55